U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06868264) titled 'C-BEYOND: Efficacy and Safety of BEM/RZR Vs. SOF/VEL in Subjects with Chronic HCV' on March 07.
Brief Summary: The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
HEPATITIS C VIRUS CHRONIC INFECTION
Intervention:
DRUG: Bemnifosbuvir-Ruzasvir (BEM/RZR)
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
DRUG: Sofosbuvir-Velpatasvir (SOF/VEL)
SOF/VEL Fixed-dose Combination ...